Compounds & interventions

GLP-1 drugs

Medicine & Biotech · covered by 111 outlets this week · tracked since 2026-10-27

Press: 61 mainstream 184 specialist 78 independent outlet-days

What it is

Evidence 9/10 · thoroughly established Uneven · 2–10 by use Signals · regulator warning

GLP-1 drugs mimic a gut hormone that slows digestion, blunts appetite and boosts insulin release. Developed for type 2 diabetes, they produced weight loss of 15 to 20 percent in trials and are now the most-covered drug class in health news. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) lead the field, with oral versions, cheaper copies and new targets such as alcohol use, kidney and heart disease, and sleep apnoea arriving behind them. Open questions are muscle loss, what happens after stopping, long-term safety and who pays.

The score describes type 2 diabetes and obesity, where the class has more than a decade of large trials and approvals. Alcohol use disorder, Alzheimer's disease and other addiction uses are still in trials.

Evidence by use or claim · 1 preclinical to 10 thoroughly established

  1. Type 2 diabetes10/10 · thoroughly established

    First approval in 2005; recommended in treatment guidelines worldwide.

  2. Obesity and weight management10/10 · thoroughly established

    Approved since 2014; large trials of several drugs in the class.

  3. Cardiovascular risk reduction9/10 · thoroughly established

    Outcome trials (LEADER, SELECT) and label indications.

  4. Chronic kidney disease in type 2 diabetes8/10 · established for some uses

    The FLOW trial (2024) and a label indication for semaglutide.

  5. Obstructive sleep apnoea8/10 · established for some uses

    Tirzepatide approved in 2024 after two phase 3 trials.

  6. MASH (fatty liver disease)7/10 · established for some uses

    Semaglutide approved in 2025 on liver-biopsy results; outcome data pending.

  7. Alcohol and other substance use disorders3/10 · early human evidence

    Observational signals and one small randomised trial.

  8. Alzheimer's disease2/10 · preclinical

    Two phase 3 trials of semaglutide missed their primary endpoint in 2025.

  • RegulatorUS labels carry a boxed warning for thyroid C-cell tumours, based on rodent studies; the human risk is considered unlikely but people with a family history of medullary thyroid cancer are excluded. source
  • TrialNausea, vomiting and diarrhoea are common during dose escalation; gallstones, rare pancreatitis and rare gastroparesis have been observed in people. source
  • RegulatorThe FDA warned about counterfeit Ozempic pens in December 2023 after hospitalisations in Europe, and cautions that compounded versions have not been shown safe or effective. source
  • RegulatorIn January 2026 the FDA asked makers to remove the suicidal-ideation warning from GLP-1 labels after reviews found no link. source
  • TrialRapid weight loss on these drugs includes some loss of muscle; how much, and whether it matters for older adults, is an open question in current trials.

This week · The FDA required a label warning on all GLP-1 drugs about NAION, a rare condition that cuts blood flow to the optic nerve, after an analysis of 126 trials.

Written by the Alivewire editors from the coverage below, 3d ago; rated 2d ago. Not medical advice; how the ratings work.

Coverage